Trichostatin a destabilizes HIF-2α through a VHL-independent but proteasome-dependent pathway in cancer cell lines and tumor xenografts

Bangladesh Journal of Pharmacology

Volumn 8, Issue 2, 2013, Pages 142-148

  Yang, Qingcheng ^a   Du, Yuzhen ^a   Cheng, Dongdong ^a   Zhang, Zhichang ^a   Du, Xinhui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Acetylation; Hypoxia inducible factor 2 ; Proteasome; Trichostatin A

Indexed keywords

HISTONE DEACETYLASE 6; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MESSENGER RNA; TRANSFER RNA; TRICHOSTATIN A; VON HIPPEL LINDAU PROTEIN;

ACETYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; GROWTH INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT;

EID: 84875500244     PISSN: 1991007X     EISSN: 19910088     Source Type: Journal    
DOI: 10.3329/bjp.v8i2.13842     Document Type: Article

References (28)

1. Bertout JA, Patel SA, Simon MC. The impact of oxygen availability on human cancer. Nat Rev Cancer. 2008; 8: 967-75.
2. Blander G, Guarente L. The Sir2 family of protein deacetylases. Annu Rev Biochem. 2004; 73: 417-35.
3. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nature Med. 2000; 6: 389-95.
4. Caro J. Hypoxia regulation of gene transcription. High Alt Med Biol. 2001; 2: 145-54.
5. Chen S, Sang N. Histone deacetylase inhibitors: the epigenetic therapeutics that repress hypoxia-inducible factors. J Biomed Biotechnol. 2011; 2011: 197946.
6. de Ruijter AJ, van Gennip AH, Caron HN, Kemp S, van Kuilenburg AB. Histone deacetylases (HDACs): characterization of the classical HDAC family. Biochem J. 2003; 370: 737-49.
7. Dioum EM, Chen R, Alexander MS, Zhang Q, Hogg RT, Gerard RD, Garcia JA. Regulation of hypoxia-inducible factor 2alpha signaling by the stress-responsive deacetylase sirtuin 1. Science. 2009; 324: 1289-93.
8. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 2003; 195: 1-16.
9. Fath DM, Kong X, Liang D, Lin Z, Chou A, Jiang Y, Fang J, Caro J, Sang N. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-alpha. J Biol Chem. 2006; 281: 13612-19.
10. Fraisi P, Mazzone M, Schmidt T, Carmeliet P. Regulation of angiogenesis by oxygen and metabolism Dev Cell. 2009; 16: 97-106.
11. Glozak MA, Sengupta N, Zhang X, Seto E. Acetylation and deacetylation of non-histone proteins. Gene. 2005; 363: 15-23.
12. Hockel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001; 28: 36-41.
13. Holmquist-Mengelbier L, Fredlund E, Lofstedt T, Noguera R, Navarro S, Nilsson H. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell. 2006; 10: 413-23.
14. Kim HJ, Bae SC. Histone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs. Am J Transl Res. 2011; 3: 166-79.
15. Kim MS, Kwon HJ, Lee YM, Baek JH, Jang JE, Lee SW, Moon EJ, Kim HS, Lee SK, Chung HY, Kim CW, Kim KW. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat Med. 2001; 7: 437-43.
16. Kong X, Lin Z, Liang D, Fath D, Sang N, Caro J. Histonedeacetylase inhibitors induce VHL and ubiquitinindependent proteasomal degradation of hypoxia-inducible factor 1alpha. Mol Cell Biol. 2006; 26: 2019-28.
17. Liang D, Kong X, Sang N. Effects of histone deacetylase inhibitors on HIF-1. Cell Cycle. 2006; 5: 2430-35.
18. Mack FA, Rathmell WK, Arsham AM, Gnarra J, Keith B, Simon MC. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth. Cancer Cell. 2003; 3: 75-88.
19. Melillo G. Hypoxia-inducible factor 1 inhibitors. Methods Enzymol. 2007; 435: 385-402.
20. Patel SA, Simon MC. Biology of hypoxia-inducible factor-2alpha in development and disease. Cell Death Differ. 2008; 15: 628-34.
21. Qian DZ, Kachhap SK, Collis SJ, Verheul HM, Carducci MA, Atadja P, Pili R. Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha. Cancer Res. 2006; 66: 8814-21.
22. Qian DZ, Wang X, Kachhap SK, Kato Y, Wei Y, Zhang L, Atadja P, Pili R. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2004; 64: 6626-34.
23. Qing G, Simon MC. Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. Curr Opin Genet Dev. 2009; 19: 60-65.
24. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010; 29: 625-34.
25. Semenza GL. Expression of hypoxia-inducible factor 1: mechanisms and consequences. Biochem Pharm. 2000; 59: 47-53.
26. Semenza GL. Hypoxia-inducible factor1 and cancer pathogenesis. IUBMB Life. 2008; 60: 591-97.
27. Semenza GL. Regulation of oxygen homeostasis by hypoxia-inducible factor 1. Physiology (Bethesda). 2009; 24: 97-106
28. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol. 2004; 14: 198-206.